newsfilter
← Latest News
Earnings Call Transcripts·

SPYRE THERAPEUTICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - SPYRE THERAPEUTICS INC

All righty. Good afternoon, everyone. I hope everyone is having a great conference. Day two of our London Healthcare Conference. It's been really great to see the attendance, and I hope everyone's having a good set of meetings. My name's Akash Chowari. I head our pharma and biotech research efforts internally within Jefferies, and we have Cameron from Spire, and one of our top picks in biotech. Cameron, why don't I hand it off to you for some intro remarks and we'll get started. Sure. So thanks for having me. Always an amazing conference. Broadly, our goal at Spire is to create a set of products that raise the bar in autoimmune disease, really by taking what we think are the best mechanisms in known diseases, creating improved versions of the antibodies against those targets, and then combining them together in what we believe are elegant, co-formulated products that can be delivered on a convenient basis. And we started in inflammatory bowel disease. We think we have three of the best monotherapies in the space, and we're enrolling a large study now to evaluate the pairwise combinations of each of them, which we think have the potential to be much better than today's standard of care in IBD. And then more recently, we've expanded our efforts in HS. This is an area like IBD, high unmet need, irreversible consequences of uncontrolled disease. And I think it's increasingly clear that TL1A and IL-17 are two of the best mechanisms in HS. We have long-acting, optimized versions of both that we'll be developing as monotherapies and or combinations, again, with the idea that we can do better than the today's standard of care. Understood. Now, I want, you know, we'll talk about combination approaches and you have phase two data sets coming up. but and this was similar to some of the times the discussion we had with apogee when you think about long-acting therapies and what they provide from a health economic perspective i feel like people think well it's a known target this is not some high science approach but adherence has a material impact on how payers view classes how um you know what actual adoption ends up being and and I don't feel like it's appreciated enough. I think people are growing more aware of that in some of the conditions that Apogee went for, but I don'T know if they necessarily appreciate that yet in UC and Crohn's, where, again, you actually have even more severe disease progression in some instances. Can you talk about what you're providing for patients and payers that is unique beyond just good targets? Yeah, I mean, I think ultimately our goal as an industry is to create products that improve the lives of patients. Nothing too complicated here. In IBD, it's a disease that every point of efficacy matters a lot. I mean, this is a disease if it's uncontrolled, you can have resections, surgeries, fibrosis, stenosis. And we've seen over the course of the last few decades, as drugs come out that are even, I think, modestly improvements over the existing standard of care, they've largely moved to those products even as the first generation went biosimilar. So we originally had Humira, Stelara, and then we saw head-to-head victories by Intivio, Trampaya, Skyrizzy, and those drugs have really taken the lion's share of the market with changes in efficacy on the order of 8 to 12 points, around 10 points of remission, even without improvements in convenience. I think what these combinations have the potential to do is deliver that level of improvement, maybe even more, while moving from drugs that are delivered every couple of weeks or intravenously to being able to be delivered, you know, four times a year as auto injectors, which I think is really a major step forward. I think very likely to improve adherence, compliance, and really reduce the downstream consequences and costs of disease that, as I mentioned, are extraordinarily costly. So I think this is, you now, it's a better product for patients. It's a product for payers. And ultimately, I think they should be highly valuable and used broadly. Understood. And then I think a part of that is, your team seems to be adamant that this really is a frontline drug opportunity. And I think if you tell that to someone who maybe wasn't familiar with your regimens, they'll always be like, well, come on, there's biosimilars out there, there're Humira out there. Why would anyone be using a brain therapy in a frontline setting? So can you talk about why you're confident that really the combination approach you're delivering is actually optimally a front-line regimen. And do you feel like that's increasingly recognized when you think about external discussions? Yeah, I think over the last, it's over a decade now, that the IBD field has moved towards top-down therapy. This really comes on the back of the profile study, which is the most important clinical study, but I think it reflects on a great deal of evidence before that. But the profile studies showed that using the best drug first leads to better long-term outcomes by a meaningful margin. And they didn't just show that in terms of patient outcomes, clinical outcomes. They also showed that it was cost-effective, too. You know, reducing surgeries, reducing hospitalizations. And again, to make this argument to the payers, you know, these somewhat, you know, apparently could be minor improvements in efficacy matter a lot and lead to, you knows, better products and better cost-effectiveness. You know? I think as we look forward, even as those first-generation drugs went biosimilar and go to a meaningfully different price point, that did not slow the growth of Intivio, Tramphia, Skyrizzy. I think, you know, in the next generation here, again, I think we can come out with products that beat those by a similar or greater margin, frankly, and be launching at the same time those drugs are still branded. And I think мы can be launching combinations at a more similar price point actually, as those existing branded drugs beat them by a clinically meaningful amount on efficacy. AndI think those drugs will end up taking the lion's share. You know, and I say we see data more and more in IBD, you know, we even saw it just a few weeks ago from AbbVie's combination, that the separation that we see early in these patients tends to widen over time, again, pointing to you want to get people on the most effective drug as soon as you can, and you want to keep them there to avoid the consequences of this disease. Understood. Last question, again in terms of where, you know, this product, the products you have can really fit. One of the things we've noticed about J&J and their Oral L23, which is a beautiful drug, they're running mild studies. So you're seeing appetite with oral biologic-like drugs, not just to be in the moderate to severe population, but really, and probably at even a lower cost, go for a mild, truly naive segment of patients. I think that's getting increasingly understood with oral, but I don't feel like it's talked enough about with long-acting injectables. is there a, I mean, how much has your team thought about that in terms of it being a market opportunity? Do you have maybe downstream, you know, plans to actually run studies in that population? And given the safety profile, let's say even for the Intivio or IL-23, where do you think biologic adoption could be in that population, which I don't think investors really model at all right now? Yeah, I think, you Know, in IBD, we're quite a ways away from complete penetration of advanced therapies. You know, in ulcerative colitis, we are still below 50% in terms of the population receiving advanced therapies. In Crohn's, we're doing better. We're more than two-thirds of the popular population receiving advance therapies there, but those numbers are going up as we learn more that you want to be on effective therapies early. I think oral therapies can be a helpful tool to actually get those numbers higher. That said, you know, in IBD, there hasn't been a case where convenience alone is good enough or you'd be willing to sacrifice safety or efficacy in exchange for convenience. I think in IBD, it is safety and efficacy first by quite a margin. And then if they're the same, we see convenience matter. So I think, you know, you and others follow the competition between the IL-23 classes. We see drugs that are both delivered Q8 weeks, one as an on-body pump, one has an auto injector. The auto injector wins by a fair margin, similar safety and efficacy, but the auto injecter wins. So when we look at the profile of our combination therapies, having long-acting co-formulatable versions of both of these at high concentrations, we think we're uniquely able to get these into auto injectors and deliver them subcutaneously, infrequently, and conveniently. Others who didn't start at the same place we did with long- acting versions that we designed for co- formulations from the outset, you see a lot of combinations that are more combinations of convenience, basically combining what they had on their shelf at the time, things being repurposed from other indications, not designed for IBD, drugs with different dosing intervals, I think at worst mixing orals and injectables, that it's hard to imagine how that gets to a convenient profile. I think our setup is unique. It is a bit of, you know, we were at the right place at the right time when the combo studies came out and showed that this was going to be the future, but we were able to pick antibodies that I think give us a unique product profile relative to everything else in development. Now, you know, it's funny, a few years ago, you know, this idea of contribution of components, which is almost a purposely vague term in the side of the FDA, but there is something that, you know, just seems nonsensical, at least to me, is that you go with a bispecific, you don't have to show contribution of components, you have higher ADAs, you often have higher viscosity, you can have worse dosing. And then seemingly the bar of a co-formulation is, you know, this draconian, it has to be stat-sig on the contribution of components. That would be, let's say, the pitch not getting more data. But we've actually gotten several data sets on how the FDA thinks about contribution to components, specifically in INI, over the last two years. Talk to us about what your teams learned? What is really the bar on contribution of components? And then remind us in terms of your assumptions for the phase twos going, reading out next year about what you expect the combo approaches to show over the monotherapy options. Yeah. I mean, at the high level, I do think it's unusually challenging in terms OF what, what should be required for this relative to, you know, multi-specific antibodies, which I think have more downsides than the co-formulations do. But I think, you know, we've solved it in what I think is a pretty elegant trial that does it all together. And that lets us answer this question in a very efficient way in terms of studying three monotherapies, three combos, and one placebo. I think one thing that's maybe not appreciated when we clarified our timing for reading out this study in third quarter of next year is that, you know, that means we'll have enrolled north of 600 patients in less than a year on this trial. I think it speaks to the enthusiasm of this community to participate in a study testing these three combinations and their differentiation relative to what else is out there being studied. In terms of what we need to see, you know, best case scenario, of course, you hit stat sig contribution of components. I think, you Know, super clear answer. That said, you Now, I think we've seen examples both in I&I, certainly outside of I& I, that it is a totality of evidence. And I think We have, You Know, clear guidance towards that as well. that it's a totality of evidence, not necessarily stat sig on any particular endpoint that you need to achieve to be able to demonstrate contribution of components. I think if we see it, easy answer. If we don't, I actually think we know what the worst case scenario is. We've seen it with other studies in IBD. Even if you don't hit it, there's a reasonable path forward here. We see that in the phase three study that J&J has launched, the Duet Encore study, still a reasonable design, two arms, nothing extraordinarily challenging. So I think we've designed the study well to achieve contribution of components. I think we're hopeful that we'll see that. If we don't, I think we still have a very viable path forward. Understood. And just remind us, in terms of the bar for Phase 2 versus Phase 3, because it does seem like Phase 3 well-powered is different than a Phase 2. What are the Phase 2 power to show in terms of what would be a stat-sig improvement on contribution components? And then what has your team thought about in terms OF what you'd want to see ideally to move forward into Phase 3 and feel confident that you could power to be stat sick yeah so we're you know we're powered about 80 to see a mid-teens delta between these arms this is you know monotherapy is against placebo or the combinations against the monotherapies in terms of and we have three shots at it right we have three combinations three monotherapys i think we have you know many ways that this could work well i think you know in terms the bar in terms what would be attractive enough as a you know winning products i come back to what we've seen commercially which is that head-to-head victories in the range of 10%, some not even 10%. Again, in the Varsity study, Antivio beats Humira by 8%, and you still see that that product has massive uptake in the market and grows really rapidly even as Humira goes biosimilar. So I think the ultimate bar is about a 10-point delta between the combinations and the best monotherapies. I think it's very likely that combinations can deliver that. Okay, understood. Now talk to me a bit about what we've learned about TL1A, right? and there are areas where it works, there's areas where it doesn't, TNF refractory versus naive. Where do you feel like TL1A really delivers in terms of best-in-class efficacy? Why would I take a TNf when I can take something that's theoretically safer? And where are there areas where, you know what, there are limitations on what this MOA can really deliver for patients? I'm trying to add them up in my head right now. I think we've seen eight different indications for TL1A between UC, Crohn's, and then six ex-IBD indications this year, at least one more to come, and then maybe a couple more down the road. I think if we stack rank them, I think the IBD results, one of the best, if not the best mechanism in IBD. I think HS is next. Actually, we see results where the efficacy looks in line with the best mechanisms in the space, and safety might even be cleaner there. And then below that, things that have not looked as good. I think our RA result might be next, actually. after HS. It hit the primary and some key secondaries there. And I think broadly, we wanted to explore the biology of TL1A, as everyone else did who owns it. But I think the right thing to do from a shareholder perspective is only advance the molecule, either as a monotherapy or a combo, when it is a best-in-indication or near-best-inindication product. I think certainly in IBD, certainly in HS. Let's see on some of these other studies that we'll read out if we have that opportunity as well. Understood. I got to give you credit, because before we even got the AFI data and we got the UEGW abstract from that Spain data set, I still remember even well in, you know, last year, you're like, look, people are underrating Intivio. We love this MOA. It's combinable. And you even said, I distinctly remember you saying, if I had a choice of picking, I would take an Intivio and IL-23 simply because we just don't have enough long-term data on TL1A and these assets are more de-risked. Now, tell me, does that mean we don't know what to combine with with TL1a? Or actually, when you look at some of the combination data sets we've seen, when we understand more about TL1B biology, do you feel like Spire actually has a differentiated view on where TL1A combinations fit, or, you know, that's still up in the air. Call your shot again. I would say our basic hypothesis is that better components are going to make better combinations. Doesn't have to be the case. You may see weird synergies and unexpected things with combinations, but I think it's a reasonable place to start to take the best individual components, combine them together, especially if they have orthogonal biology. And, you Know, again, a little bit lucky that the ones that we're working on do. You know, again, I have been biased towards alpha-4 for a while because it's such a unique mechanism in IBD. It's a trafficking mechanism relative to these inflammatory cytokines. So I think the probability that that's going to be additive with the anti-cytokine agents, I believe, is very high. I believe it will add to both of these components. You now, so I said I liked alpha-3 and alpha-23. I think we now have very good evidence that that's likely to work. In Crohn's, I think it's just as likely, if not more so, to work in ulcerative colitis, where alpha-4, beta-7 might be even better. And I still wouldn't say that TL1A are not going to add up as well. It's an individual mechanism. TL1a might be the best of the three, and so I think is quite likely to add with the other two as well, so we don't pick our favorite child yet. That's why we're testing them head-to-head against each other. I think my base case actually is we're going to have more than one of the best combinations in this space, and I think our base case is that we'll be advancing more than one of these to phase three, and i think they could be some of the best products ultimately. And to put a finer point, okay, so let's say IL-23 and TIVIO, your number one option right now, based on the evidence we've seen, what would be, because you have three combos reading out next year, what, if you're going to look at the scientific literature, the emerging data, where do you also feel like you could deliver best-in-class efficacy? Yeah, I mean, you mean with these combinations? I mean ulcerative colitis and Crohn's, obviously this is the right place for them. You know, I do see, you know, we're going to use the data next year as the primary determinant of what advances. You know, we have all these hypotheses about the biology, but we're testing them head-to-head in a controlled trial. That's by far the best evidence. I think we'll have that before anyone else. And I think the nice thing is that regardless of what wins, I think we have the optimized version of it. There's not a better version of one of these combos out there. And so we'll both be first and best with whichever combo we choose to advance first. You know, when we advance to phase three, we're expecting to advance the first one. And then realistically, as soon as we stop enrolling the first combination in phase three, I think we can move on to the second and maybe and so on. And I think, you know, we actually have quite a lead on many of these combinations. AndI think we may have multiple of them on market before others do. And how much, when we think about the combinations, do you ultimately move into phase three? To your point, duet, there's a clear refractory signal that we're seeing. Now, your team's talked about we want to be, you know, biologic-like price, frontline setting for one of these combos. But you have the opportunity to stratify the market where it's like, hey, we have a frontline regimen. Then we also have a regimen that might work, particularly in refractory patients who have been already on multiple biologics. Is that a possibility when we think about which assets you end up moving forward? Or really, it's all going to be about the frontline potential when we think about moving into phase three? Yeah, I mean, when you look at the distribution of revenue in IBD, the top three drugs take more than two-thirds of it. And they kind of always have. And it's a little bit dealer's choice in terms of which drug physicians want to start on. And then the most likely thing that they pick next is another of those top three drugs and then when they lose response to that the most likely thing they move to is the third best drug in that space and you know i think today you know we've talked about which biologists that are i do think in five you know five to ten years those are going to be combo one combo two combo three these drugs are goingto deliver greater efficacy than the existing monotherapies on the market we have great evidence that treating early with more effective drugs leads to better long-term outcomes, and they're cost-effective. I think we can price these combinations rationally, and I think they can be, you know, multiple early-line products, and then only would you, you know use these monotherapies after you've, you exhausted your potential for combinations. I think most likely folks are going to pick whatever combination they like first, and then they'll switch to a combination with at least one new mechanism. I think, we have multiple of those. Right. Now, you, know, when we think about when does Spire get de-risked, right? And I mean, it's an unusual conversation for a company that's going into phase two studies. But part of me thinks like, look, we now have the App-V data. We now have emerging data about combination use. There's a growing realization about which combos work and which ones don't, right. And I don't think we were in that same place when we saw the initial duet data and we're all trying to read, you know, J&J's body language. I think there's been more de-risking. So when you think about external de-risking versus, you know, you have to show that, you know, your drugs work as expected, do you feel like there has already been a shift when you think About strategic discussions that we know some of these combos are going to work, we do see the orthogonal biology, and really, we just want to make sure that the co-forms are behaving as expected? Right? Like, has the de- risking to a certain extent already happened? I'm not sure we've seen many data sets where combinations aren't at least somewhat additive. Even in cases where the monotherapy components don't work very well, say in the context of you failed a great TNF and then you're getting a different TNf and that component adds very little on its own or does very little on his own, it's still quite additive when combined with something else. We see the real-world registries in Spain. We see real- world registries all over the world where combos are at least partially additive. It also should not be surprising. This is a heterogeneous disease with multiple pathways driving the advancement of the disease. Blocking more than one pathway should be additive. I think this AbbVie data is the strongest evidence, but the Vega study was great evidence, too. Look, I think we've had increasing evidence over time that combinations are going to be additive, I think the design of our study, we're going to have 50% to 60% naive patients in our trial, 40% to 50% refractory, but we'll limit the number of patients who will have failed our existing mechanisms. I think it's very likely that we're going to see a reasonable amount of additivity between the three best mechanisms in this space. I think those are going to look like good combinations. Understood. And maybe more of a question for you because you've had a very ambitious outlook for Aspire and I think there's good reason to think that. And part of that's been like, look, we have a moat in the sense that the capital needed to develop these co-forms, the amount of indications we're doing, this is a multi-asset, multi-product story, and therefore the strategic value, the value that you think about Spire, was always going to be larger than maybe some of your sister companies, let's put it that way. But I think we're also seeing, in terms of the error bars, right, like you have a better sense of the room opportunity, you have the better sense OFHS, you know, you're not going to have a better sense where the GI combos are fitting. So do you feel like, on your end too, you're also getting to a more narrow range about what you feel like Spire can actually provide from a strategic perspective. I do. I mean, you know, as we talked about, eight indications for TL1A got explored over the last few years. We've seen the ones where it works best. I think the story has gotten simpler. It's basically the three best mechanisms and their combos in IBD, the two best mechanisms in HS, and its combination there. You know, I think on the IBD side, when we're launching, this is going to be about a $40 billion market, and I think the top three drugs are going to continue to take two-thirds of it or more. HS is, you know, it's a much less mature market, and so, you Know, the growth of that and how much combos take relative to monos is maybe a bit less certain. But in IBD, this opportunity is still massive. I still think we have three of the best, if not the best products in development there, and I thing they will take a large chunk of this huge market. Understood. And just maybe lastly, okay, so there's a narrowing and let's say sharpening of what the strategic value is internally with Inspire. Is that same kind of focus in terms of sharpening what this product can deliver and an appreciation about this is really a multi-asset strategy that you could be buying? Do you feel like that's getting reflected externally as well? Look, yeah, we've had a great year in terms of appreciation for what we're doing. Certainly in IBD, I think the HS story is new, but I don't think it accounts for what these could take in the ultimate market. Of course, we've got to prove it out. There's always risk and time ahead to do that. But I think ultimately, these products have a potential to meaningfully move the bar forward in huge autoimmune markets. I think we can deliver huge amounts to the patients with these diseases. And then I think there's still plenty of room to grow from a valuation perspective as well. Understood. And then really last question, let's, we may be talking at the same time in London, we never know. But by the time we're done with the phase twos, do you feel like we'll get to a point where both externally and internally, we're getting to the right lens about the value of this company? you know it's always incremental right you know i think the data set that we're going to deliver next year will show how many indication leading products we have in ibd i think it's you know zero to six i which you know there's still a reasonable amount of range there but i i think you know the the combinations i think are some of the best bets in the space i think the data we've shown in terms of proving that the monotherapies work at least as well as we expect should de-risk that as well more and more combination data sets showing that combos should add up, I think it's reasonably likely we're going to have multiple combinations that are leading on efficacy, leading on safety, leading on convenience, and some of the first into phase three. I think it's a good setup. Makes sense. I agree. Hey, thank you so much. I really do appreciate it.

Company
SPYRE THERAPEUTICS INC
Keywords
SPYRE THERAPEUTICS INC